Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Hot Flashes 1

Interventions

pembrolizumab 604Carboplatin 374Paclitaxel 283Cisplatin 270Gemcitabine 252Pemetrexed 194Bevacizumab 191Docetaxel 186Nivolumab 180Injections 169Cyclophosphamide 150atezolizumab 139Fluorouracil 134Capecitabine 133Oxaliplatin 132Dexamethasone 128durvalumab 113Fulvestrant 113130-nm albumin-bound paclitaxel 110fludarabine 103Cetuximab 100Leucovorin 97Rituximab 95venetoclax 90Lenalidomide 83enzalutamide 77Prednisone 77Azacitidine 74Irinotecan 73Doxorubicin 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × fezolinetant × 1 year × Clear all
NCT06440967 2026-04-06

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

Astellas Pharma Inc

Phase 3 Active not recruiting
984 enrolled

Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡